Shuhong Ming1, Jing Gao, Tieying Sun. 1. Department of Respiratory Medicine, Beijing Hospital Ministry of Health, Beijing 100730, China. qzf301@sohu.com
Abstract
BACKGROUND AND OBJECTIVE: The expression of TSLC1 is downregulated or abrogated in many kinds of tumors, and its downregulation is highly associated with DNA hypermethlyation. The aim of this study is to explore the relationship between TSLC1 silencing and DNA methylation of its promoter region in lung cancer cells. METHODS: We detected the expression pattern of TSLC1 in human normal lung tissue and three lung cancer cell lines (A549, NCI-H446 and Calu-3) by semi-quantitative RT-PCR and Real-time PCR. Then we detected the status of DNA methylation in TSLC1 promoter region with bisulfite sequencing in above normal lung tissue and lung cancer cell lines. After treatment of above cell lines with the inhibitor of DNA methyltransferase 5-Aza-2-deoxycytidine (5-Aza-dC), we detected the expression change of TSLC1 by Real-time PCR before and after the treatment of 5-Aza-dC. RESULTS: There was no methylation in TSLC1 promoter region in normal lung tissue and A549 cell line in which TSLC1 expressed; while there was DNA hypermethylation in TSLC1 promoter region in NCI-H446 and Calu-3 cell lines in which TSLC1 was abrogated, also the expression of TSLC1 in NCI-H446 and Calu-3 cell lines could be restored after treatment of 5-Aza-dC. CONCLUSION: The silencing of TSLC1 in lung cancer cells is due to the hypermethylation of its promoter region.
BACKGROUND AND OBJECTIVE: The expression of TSLC1 is downregulated or abrogated in many kinds of tumors, and its downregulation is highly associated with DNA hypermethlyation. The aim of this study is to explore the relationship between TSLC1 silencing and DNA methylation of its promoter region in lung cancer cells. METHODS: We detected the expression pattern of TSLC1 in human normal lung tissue and three lung cancer cell lines (A549, NCI-H446 and Calu-3) by semi-quantitative RT-PCR and Real-time PCR. Then we detected the status of DNA methylation in TSLC1 promoter region with bisulfite sequencing in above normal lung tissue and lung cancer cell lines. After treatment of above cell lines with the inhibitor of DNA methyltransferase 5-Aza-2-deoxycytidine (5-Aza-dC), we detected the expression change of TSLC1 by Real-time PCR before and after the treatment of 5-Aza-dC. RESULTS: There was no methylation in TSLC1 promoter region in normal lung tissue and A549 cell line in which TSLC1 expressed; while there was DNA hypermethylation in TSLC1 promoter region in NCI-H446 and Calu-3 cell lines in which TSLC1 was abrogated, also the expression of TSLC1 in NCI-H446 and Calu-3 cell lines could be restored after treatment of 5-Aza-dC. CONCLUSION: The silencing of TSLC1 in lung cancer cells is due to the hypermethylation of its promoter region.
Expression pattern of TSLC1 in human normal lung tissue and lung cancer cell lines. Expression levels of TSLC1 in human normal lung tissue and three lung cancer cell lines by semi-quantitative RTPCR (A) and Real-time PCR (B), GAPDH used as endogenous control.
TSLC1在正常人肺组织及肺癌细胞系中的表达谱。半定量RT-PCR方法(A)及Real-time PCR方法(B)检测TSLC1在人正常肺组织及3株肺癌细胞系中的表达水平,GAPDH作为内对照。Expression pattern of TSLC1 in human normal lung tissue and lung cancer cell lines. Expression levels of TSLC1 in human normal lung tissue and three lung cancer cell lines by semi-quantitative RTPCR (A) and Real-time PCR (B), GAPDH used as endogenous control.
The distribution of CpG island in 5' non-coding region of TSLC1 gene. Each vertical short stick at the bottom of figure indicates one CpG dinucleotide, the blue region represents the CpG island and the translation start site "A" as +1.
TSLC1基因5'非编码区的CpG岛分布。图下方的每条竖线代表一个CpG二核苷酸,蓝色区域代表CpG岛,翻译起始位点的“A”定义为+1。The distribution of CpG island in 5' non-coding region of TSLC1 gene. Each vertical short stick at the bottom of figure indicates one CpG dinucleotide, the blue region represents the CpG island and the translation start site "A" as +1.
Methylation pattern of TSLC1 in one human normal lung tissue and three lung cancer cell lines. A, B, C, D represented the methylation pattern of TSLC1 promoter in normal lung tissue, A549, NCI-H446 and Calu-3 cell lines, respectively. Each vertical short stick at the top of each figure indicates one CpG dinucleotide, and TSLC1 promoter region detected is located from -556 bp to -336 bp with the translation start site "A" as +1. Eleven CpG sites were included in this fragment and CpG sites which are marked from 1 to 6 are very important according to the papers. Black dot means methylated CpG while white dot means non-methylated CpG.
TSLC1在1例正常肺组织和3株肺癌细胞系中的甲基化谱式。A、B、C、D分别代表正常肺组织、A549细胞、NCI-H446细胞和Calu-3细胞中TSLC1启动子区的甲基化模式。每个图顶端的每条竖线代表一个CpG二核苷酸,被检测的TSLC1启动子区位于TSLC1基因组的-556 bp到-336 bp处,翻译起始位点的“A”定义为+1。被检测的TSLC1启动子区共包括11个CpG二核苷酸,其中标记为1号-6号的CpG位点是文献报道的重点检测位点。黑色圆圈表示发生甲基化的CpG;白色圆圈表示未发生甲基化的CpG。Methylation pattern of TSLC1 in one human normal lung tissue and three lung cancer cell lines. A, B, C, D represented the methylation pattern of TSLC1 promoter in normal lung tissue, A549, NCI-H446 and Calu-3 cell lines, respectively. Each vertical short stick at the top of each figure indicates one CpG dinucleotide, and TSLC1 promoter region detected is located from -556 bp to -336 bp with the translation start site "A" as +1. Eleven CpG sites were included in this fragment and CpG sites which are marked from 1 to 6 are very important according to the papers. Black dot means methylated CpG while white dot means non-methylated CpG.
Expression pattern of TSLC1 in lung cancer cell lines before and after the treatment of 5-Aza-dC. A, B, C represented the expression level of TSLC1 in A549, NCI-H446 and Calu-3 cell lines before and after the treatment of 5-Aza-dC, respectively; *P < 0.05 compared with control.
TSLC1在5-Aza-dC处理肺癌细胞系前后的表达谱。A、B、C分别代表TSLC1在5-Aza-dC处理A549细胞、NCI-H446和Calu-3细胞前后的表达水平;与对照组相比,*P < 0.05。Expression pattern of TSLC1 in lung cancer cell lines before and after the treatment of 5-Aza-dC. A, B, C represented the expression level of TSLC1 in A549, NCI-H446 and Calu-3 cell lines before and after the treatment of 5-Aza-dC, respectively; *P < 0.05 compared with control.
Authors: Louise van der Weyden; Mark J Arends; Oriane E Chausiaux; Peter J Ellis; Ulrike C Lange; M Azim Surani; Nabeel Affara; Yoshinori Murakami; David J Adams; Allan Bradley Journal: Mol Cell Biol Date: 2006-05 Impact factor: 4.272
Authors: Renske D M Steenbergen; Debbie Kramer; Boudewijn J M Braakhuis; Peter L Stern; René H M Verheijen; Chris J L M Meijer; Peter J F Snijders Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Evi Michels; Jasmien Hoebeeck; Katleen De Preter; Alexander Schramm; Bénédicte Brichard; Anne De Paepe; Angelika Eggert; Geneviève Laureys; Jo Vandesompele; Frank Speleman Journal: BMC Cancer Date: 2008-06-17 Impact factor: 4.430